.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Cantor Fitzgerald
Argus Health
Teva
Dow
Harvard Business School
Medtronic
Healthtrust
Cerilliant

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021977

« Back to Dashboard

NDA 021977 describes VYVANSE, which is a drug marketed by Shire Development and Shire Dev Llc and is included in two NDAs. It is available from four suppliers. There are eighteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VYVANSE profile page.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Four suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

Summary for 021977

Tradename:1
Applicant:1
Ingredient:1
Patents:18
Therapeutic Class:Central Nervous System Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021977

Medical Subject Heading (MeSH) Categories for 021977

Suppliers and Packaging for NDA: 021977

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977 NDA Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC 35356-751 35356-751-30 30 CAPSULE in 1 BOTTLE (35356-751-30)
VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977 NDA Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC 35356-751 35356-751-60 60 CAPSULE in 1 BOTTLE (35356-751-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength30MG
Approval Date:Feb 23, 2007TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 14, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Jan 30, 2018
Regulatory Exclusivity Use:MODERATE TO SEVERE BINGE EATING DISORDER (BED)
Patent:► SubscribePatent Expiration:Feb 24, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Moodys
Daiichi Sankyo
Cantor Fitzgerald
Express Scripts
Citi
McKesson
Cerilliant
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot